Gb Sciences, Inc. (OTCQB:GBLX)

Gb Sciences, Inc. (OTCQB:GBLX) is a phytomedical research and biopharmaceutical drug development company. Our goal is to create patented formulations of plant-inspired, optimized therapeutic mixtures for the prescription drug market to treat a variety of conditions.

Gb Sciences’ novel drug discovery platform has yielded 5 issued US and 3 issued international patents, as well as 10 US and 35 international patent-pending applications. In our drug development pipeline, we have four preclinical stage programs, and our lead Parkinson’s disease therapeutic program is being prepared for a First-in-Man clinical trial.

Upcoming Events

Gb Sciences presenting at TMED July 12, 2021
Gb Sciences presenting at SACHS April 29, 2021
Gb Sciences presenting at Precision June 8-9, 2021

Most Recent Investor Presentation

Gb Sciences’ Drug Development Programs

Letter to Shareholder's

GBLX Stock Price

The GBLX stock price will be updated periodically, but there may be a lag with respect to real-time stock quotes

SEC Filings for Gb Sciences, Inc.

Latest News from Gb Sciences

Gb Sciences’ Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President

Gb Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals

Gary Herman Joins GB Sciences’ Subsidiary GbS Global Biopharma as Advisory Director

Media Contact

Alexis Quintal

alexis@newswire.com